| scholarly article | Q13442814 |
| P50 | author | Tejas Patil | Q88229320 |
| P2093 | author name string | Dara L Aisner | |
| D Ross Camidge | |||
| Paul A Bunn | |||
| Robert C Doebele | |||
| Mark Hancock | |||
| Daniel W Bowles | |||
| Anh T Le | |||
| William T Purcell | |||
| Derek E Smith | |||
| P2860 | cites work | Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer | Q89870010 |
| ROS1 rearrangements define a unique molecular class of lung cancers | Q27851700 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Crizotinib in ROS1-rearranged non-small-cell lung cancer. | Q27853075 | ||
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
| Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort | Q27853124 | ||
| Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors | Q27853214 | ||
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs | Q34175045 | ||
| Identifying and targeting ROS1 gene fusions in non-small cell lung cancer | Q34295696 | ||
| Molecular Pathways: ROS1 Fusion Proteins in Cancer | Q34347504 | ||
| A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer | Q34760642 | ||
| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. | Q35164218 | ||
| Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience | Q35541778 | ||
| Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer | Q36016428 | ||
| Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer | Q36422709 | ||
| Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions | Q37038500 | ||
| Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. | Q37350770 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway | Q38002468 | ||
| Acquired resistance to TKIs in solid tumours: learning from lung cancer | Q38224967 | ||
| Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer | Q38371667 | ||
| Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement | Q38402702 | ||
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. | Q38645064 | ||
| Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. | Q39285861 | ||
| Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). | Q41636361 | ||
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer | Q47450132 | ||
| Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial | Q47599265 | ||
| Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer. | Q47900903 | ||
| Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer | Q54118729 | ||
| Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer. | Q54980085 | ||
| Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis | Q70211565 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q88151876 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1717-1726 | |
| P577 | publication date | 2018-07-05 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib | |
| P478 | volume | 13 |
| Q98293214 | Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer |
| Q89861115 | Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers |
| Q98293333 | Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? |
| Q92151665 | Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations |
| Q91981740 | Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours |
| Q91981779 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials |
| Q91026096 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial |
| Q90399052 | Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date |
| Q98223093 | ROS1-dependent cancers - biology, diagnostics and therapeutics |
| Q91638768 | Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis |
| Q98613555 | Role of imaging biomarkers in mutation-driven non-small cell lung cancer |
| Q89666580 | Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion |
| Q57495887 | Targeting rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors |
| Q89497176 | The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era |
| Q92163538 | The roles of patient groups in fostering cancer research |
| Q93009434 | Time to tackle the blood-brain barrier in HER2-mutant lung cancer |
Search more.